Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

This study has been terminated.
(Extreme toxicity of Pertuzumab and Erlotinib combination)
Genentech, Inc.
Information provided by (Responsible Party):
Pamela L. Kunz, Stanford University Identifier:
First received: July 23, 2009
Last updated: November 9, 2011
Last verified: November 2011
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2010
  Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)